The estimated Net Worth of Barbara Lopez Kunz is at least $72 dollars as of 1 June 2024. Barbara Kunz owns over 88 units of Aptevo Therapeutics Inc stock worth over $71 and over the last 8 years Barbara sold APVO stock worth over $0.
Barbara has made over 4 trades of the Aptevo Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Barbara exercised 88 units of APVO stock worth $32 on 1 June 2024.
The largest trade Barbara's ever made was buying 10,000 units of Aptevo Therapeutics Inc stock on 10 June 2019 worth over $8,500. On average, Barbara trades about 1,074 units every 140 days since 2016. As of 1 June 2024 Barbara still owns at least 198 units of Aptevo Therapeutics Inc stock.
You can see the complete history of Barbara Kunz stock trades at the bottom of the page.
Barbara's mailing address filed with the SEC is 2401 4TH AVENUE, SUITE 1050, SEATTLE, WA, 98121.
Over the last 8 years, insiders at Aptevo Therapeutics Inc have traded over $17,157,676 worth of Aptevo Therapeutics Inc stock and bought 1,998,342 units worth $25,387,921 . The most active insiders traders include Kevin Ctang Capital Managem..., Fuad El Hibri y Daniel Abdun Nabi. On average, Aptevo Therapeutics Inc executives and independent directors trade stock every 38 days with the average trade being worth of $22,185. The most recent stock trade was executed by So Young Kwon on 8 August 2024, trading 213 units of APVO stock currently worth $77.
aptevo therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. we leverage the innovative adaptir™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. based in seattle, washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technology. as a result, aptevo has been able to attract some of the most innovative minds in the field. many of our team members have notable experience with other pioneering biotech companies including trubion, zymogenetics, immunex, dendreon, and vlst. at aptevo therapeutics, our core values of ownership and collaboration—combined with a history of innovation, dedication, and development—are positioning aptevo therapeutics to develop the science of what’s next in biotechnology.
Aptevo Therapeutics Inc executives and other stock owners filed with the SEC include: